Loading
Unresectable pleural mesothelioma first line, especially non-epithelioid
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Nivolumab Monoclonal antibody (anti-PD-1) | 360 mg every 3 weeks | IV | D1, 22 | |
Ipilimumab Monoclonal antibody (anti-CTLA-4) | 1 mg/kg every 6 weeks | IV | D1 |
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.